Philipp Ziegler

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

Journal: NPJ breast cancer

Published: November 29, 2025

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Journal: Breast cancer research and treatment

Published: October 24, 2025

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.

Journal: International journal of cancer

Published: July 08, 2025

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 05, 2025

Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022.

Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022.

Journal: Breast care (Basel, Switzerland)

Published: May 22, 2025

Adherence to digital pregnancy care - lessons learned from the SMART start feasibility study.

Adherence to digital pregnancy care - lessons learned from the SMART start feasibility study.

Journal: NPJ digital medicine

Published: May 08, 2025

Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality.

Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality.

Journal: BMC immunology

Published: November 28, 2024

Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.

Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.

Journal: Precision clinical medicine

Published: September 22, 2024

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

Journal: BMC cancer

Published: January 26, 2024

Showing 1-9 of 9

Last Updated: 09/26/2026